Atrial Septal Defect - Exercise Capacity and Pulmonary Hypertension

Study Purpose

The purpose of the study is to compare exercise capacity, cardiac contractility, pulmonary vascular pressures and heart rate variability between patients with an atrial septal defect and healthy controls.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Yes
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - 18 years and above.
  • - Informed consent to participate.
  • - Patients: Diagnosed with an atrial septal defect.
More than 3 years have passed since closure of the atrial septal defect.
  • - Controls: No history of heart or lung disease.

Exclusion Criteria:

  • - Lung disease.
  • - Ischemic heart disease.
  • - Diabetes.
  • - Hypertension.
  • - Valve pathology.
  • - Patients: Concomitant heart disease - Controls: Usage of prescription drugs interfering with the cardiopulmonary function.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03565471
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

University of Aarhus
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Active, not recruiting
Countries Denmark
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Atrial Septal Defect, Pulmonary Hypertension
Additional Details

1. Background Patients born with atrial septal defect (ASD) in the heart, have long been assumed healthy after closure of their defect. However, recent studies show, that despite closure of the ASD the risks of arrhythmia, stroke and pneumonia are increased. It is also shown that ASD patients die earlier than the background population and the cause of death is most often cardiac. The reason for this higher mortality and morbidity is unknown and the scope of this thesis. 2. Aim To determine if closed (both surgical and transcatheter) ASD patients have reduced exercise capacity, impaired right and left ventricular function, increased pressure in the pulmonary system, and reduced heart rate variability when compared with healthy controls. The investigators will also examine if method of closure is of importance. 3. Hypothesis Primary endpoint: The shunting effect alters the hemodynamic in the ASD heart resulting in lower cardiopulmonary exercise capacity when compared with healthy controls. Secondary endpoints: The shunting effect alters the hemodynamic in the ASD heart when compared with healthy controls resulting in

  • - Impaired force frequency relationship with a reduction in contractility at optimal heart rate.
  • - Increased pulmonary arterial pressure.
  • - Twice as many ASD patients with decreased heart rate variability.
Surgical closure is thought to have a higher impact on the ventricular function than catheter closure resulting in
  • - Lower contractility in the surgically closed patients as compared to the catheter closure as evaluated by force frequency.
  • - Twice as many surgically closed patients with decreased heart rate variability compared to catheter closed patients.
4. Materials and methods 4.1) Power calculation The number of participants needed in the project is calculated based on the exercise capacity test, which is the primary endpoint. The normal exercise test result is 48 ml O2/kg/min with a standard deviation of 7 ml O2/kg/min. With an expected difference between groups and healthy controls of 15% and a power of 85%, the number of patients needed in each group is 18. Possible drop-outs are taken into account and therefore 20 participants will be included in each ASD group, they will each be matched one to one with controls, resulting in a total of 80 project participants. The secondary endpoints are of a more explorative character, why 20 ASD patients in each group is assumed to be sufficient. 4.2) Exercise capacity, force frequency relationship and pulmonary hypertension 4.2.1) The exercise capacity test is conducted on a semi-supine bicycle, while the patients wears a mask measuring the ventilation, oxygen uptake, carbon dioxide release and respiratory exchange rate. Patients pedal until maximal exhaustion, which should be obtained after 8-12 minutes. 4.2.2) During exercise testing, the force frequency relationship is examined using echocardiography. 4.2.3) A Swan-Ganz catheter is used to measure right-sided hemodynamic pressures and blood saturation. 4.3) Heart rate variability Electrocardiographic (ECG) activity and heart rate variability will be monitored using a 2-channel Holter monitor. The data will be analyzed with the Pathfinder analysis software. 5. Statistical analysis Results for each group will be expressed as means standard deviation or median range or 95% confidence intervals. One way analysis of variance (ANOVA), paired t-tests and regression analyses will be performed. Analyses will be adjusted for age and sex. The issue of multiple testing/multiple comparisons may arise and only relevant comparisons and analyses will be performed.

Arms & Interventions

Arms

: ASD patients with surgical closure

Patients diagnosed with an ASD who have had a surgical closure of the defect more than 3 years ago. Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants.

: ASD patients with transcatheter closure

Patients diagnosed with an ASD who have had a transcatheter closure of the defect more than 3 years ago. Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants.

: Controls

Controls who do not have any cardiac or pulmonary diagnoses nor use prescription drugs that may affect the cardiopulmonary function. Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants.

Interventions

Diagnostic Test: - Echocardiography

Standard echocardiography.

Diagnostic Test: - Right side catheterization

Right side catheterization with the purpose of measuring pulmonary vascular pressures and blood saturation.

Diagnostic Test: - Exercise test

Exercise test on a supine bicycle with gradual increase in work load while wearing a mask that measures ventilation, oxygen uptake, carbon dioxide release and respiratory exchange rate.

Diagnostic Test: - Holter monitor

Holter monitor worn for 2 whole days registering heart rate.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Aarhus, Denmark

Status

Address

Dept. of Cardiothoracic & Vascular Surgery, Aarhus University Hospital

Aarhus, ,

For more information, please contact PHA at Research@PHAssociation.org and refer to the terms of service below.

Submit Feedback

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation in a clinical trial or study.